MicroRNA-135a and -200b, potential Biomarkers for Alzheimer's disease, regulate β secretase and amyloid precursor protein

Brain Research

Volumn 1583, Issue 1, 2014, Pages 55-64

  Liu, Chen Geng ^a   Wang, Jin Ling ^a   Li, Lei ^a   Xue, Li Xiang ^b   Zhang, Yue Qi ^a   Wang, Pei Chang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Microrna; secretase

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; MICRORNA; MICRORNA 135A; MICRORNA 200; MICRORNA 429; UNCLASSIFIED DRUG; APP PROTEIN, HUMAN; BIOLOGICAL MARKER; MIRN135 MICRORNA, HUMAN; MIRN135 MICRORNA, MOUSE; MIRN200 MICRORNA, HUMAN; MIRN200 MICRORNA, MOUSE; MIRN429 MICRORNA, HUMAN; MIRN429 MICRORNA, MOUSE; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; SECRETASE;

3' UNTRANSLATED REGION; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CEREBROSPINAL FLUID; COMPARATIVE STUDY; CONTROLLED STUDY; DEREGULATION; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; UPREGULATION; WESTERN BLOTTING; WILD TYPE MOUSE; ANIMAL; CELL CULTURE; GENETICS; HEK293 CELL LINE; HIPPOCAMPUS; METABOLISM; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; HEK293 CELLS; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, TRANSGENIC; MICRORNAS; MILD COGNITIVE IMPAIRMENT; PRESENILIN-1;

EID: 84922678600     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2014.04.026     Document Type: Article

References (40)

1. Anderson, J.J., et al., 2005. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem. Pharmacol. 69 (4), 689-698.
2. Bartel, D.P., 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2), 281-297.
3. Blennow, K., et al., 2010. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6 (3), 131-144.
4. Ceruti, S., et al., 2011. Oxygen-glucose deprivation increases the enzymatic activity and the microvesicle-mediated release of ectonucleotidases in the cells composing the blood-brain barrier. Neurochem. Int. 59 (2), 259-271.
5. Chen, Y., et al., 2012. Alzheimer's p-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of p-amyloid. J. Neurosci. 32 (33), 11390-11395.
6. Dassow, H., Aigner, A., 2013. MicroRNAs (miRNAs) in colorectal cancer: from aberrant expression towards therapy. Curr. Pharm. Des. 19 (7), 1242-1252.
7. Delay, C., et al., 2012. MicroRNAs in Alzheimer's disease. Neurobiol. Dis. 46 (2), 285-290.
8. Delay, C., et al., 2011. Alzheimer-specific variants in the 3'UTR of Amyloid precursor protein affect microRNA function. Mol. Neurodegener 6, 70.
9. Eulalio, A., Schulte, L., Vogel, J., 2012. The mammalian microRNA response to bacterial infections. RNA Biol. 9 (6), 742-750.
10. Hebert, S.S., et al., 2010. Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum. Mol. Genet. 19 (20), 3959-3969.
11. Hebert, S.S., De. Strooper, B., 2009. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 32 (4), 199-206.
12. Henriksen, K., et al., 2014. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 10, 115-131.
13. Junn, E., Mouradian, M.M., 2012. MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol. Ther. 133 (2), 142-150.
14. Junn, E., Mouradian, M.M., 2010. MicroRNAs in neurodegenerative disorders. Cell Cycle 9 (9), 1717-1721.
15. Lanz, T.A., et al., 2004. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2 S)-2- (3, 5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7 S)-5-methyl- 6-oxo-6, 7-dihydro-5 H-dibenzo[b, d]azepin-7-yl]-L- Alaninamide (LY-411575). J. Pharmacol. Exp. Ther. 309 (1), 49-55.
16. Liu, C.G., et al., 2007. 17Beta-oestradiol regulates the expression of Na+/K+-ATPase beta1-subunit, sarcoplasmic reticulum Ca2+-ATPase and carbonic anhydrase iv in H9C2 cells. Clin. Exp. Pharmacol. Physiol. 34 (10), 998-1004.
17. Lee, Y., et al., 2003. The nuclear RNase III Drosha initiates microRNA processing. Nature 425 (6956), 415-419.
18. Leuven, F., 2000. Single and multiple transgenic mice as models for Alzheimer's disease. Prog. Neurobiol. 61 (3), 305-312.
19. Lewczuk, P., et al., 2010. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: A multicenter study. Mol. Psychiatry 15 (2), 138-145.
20. Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) method. Methods 25 (4), 402-408.
21. Long, J.M., Lahiri, D.K., 2011. MicroRNA-101 downregulates Alzheimer's amyloid-p precursor protein levels in human cell cultures and is differentially expressed. Biochem. Biophys. Res. Commun. 404 (4), 889-895.
22. Ma, R., Jiang, T., Kang, X., 2012. Circulating microRNAs in cancer: origin, function and application. J. Exp. Clin. Cancer Res. 31, 38.
23. Matthias, K., et al., 2003. Segregated expression of AMPA-type glutamate receptors and glutamate transporters defines distinct astrocyte populations in the mouse hippocampus. J. Neurosci. 23 (5), 1750-1758.
24. Mitchell, P.S., et al., 2008. Circulating microRNAs as stable blood- based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105 (30), 10513-10518.
25. Parnetti, L., et al., 2012. Performance of ap1-40, ap1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J. Alzheimers Dis. 29 (1), 229-238.
26. Patel, N., et al., 2008. MicroRNAs can regulate human APP levels. Mol. Neurodegener 3, 10.
27. Schonrock, N., et al., 2012. MicroRNA networks surrounding APP and amyloid-p metabolism-implications for Alzheimer's disease. Exp. Neurol. 235 (2), 447-454.
28. Schonrock, N., et al., 2010. Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS One 5 (6), e11070.
29. Singer, O., et al., 2005. Targeting BACE-1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8 (10), 1343-1349.
30. Snyder, H.M., et al., 2014. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 10, 109-114.
31. Stanciu, M., et al., 2000. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J. Biol. Chem. 275 (16), 12200-12206.
32. Tan, L., et al., 2013. Non-coding RNAs in Alzheimer's disease. Mol. Neurobiol. 47 (1), 382-393.
33. Teplyuk, N.M., et al., 2012. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro. Oncol. 14 (6), 689-700.
34. Wang, W.X., et al., 2011. Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta. Neuropathol. 121 (2), 193-205.
35. Wei, P.C., et al., 2011. Matrix metalloproteinase-12 leads to elastin degradation in BALB/c mice with eosinophilic meningitis caused by Angiostrongylus cantonensis. Int. J. Parasitol. 41 (11), 1175-1183.
36. Xu, B., et al., 2011. Calcium signaling is involved in cadmium- induced neuronal apoptosis via induction of reactive oxygen species and activation of MAPK/mTOR network. PLoS One 6 (4), e19052.
37. Yang, L.B., et al., 2003. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9 (1), 3-4.
38. Zetterberg, H., et al., 2008. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch. Neurol. 65 (8), 1102-1107.
39. Zhang, Y., et al., 2010. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell 39 (1), 133-144.
40. Zhong, Z., et al., 2007. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch. Gen. Psychiatr. 64 (6), 718-726.